360b / Shutterstock.com
The English High Court has ruled that Pfizer’s second medical use patent covering its drug Lyrica (pregabalin) is invalid and that the pharmaceutical company is liable for making “groundless threats” of infringement.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Pfizer; Lyrica; Allergan; patent infringement; English High Court; Mylan